Clinical trial
Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer
NCT02430974 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2011
- Completion date
- January 31, 2018
- Enrollment
- 50 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.